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Background: Modular nanotransporters (MNT) are recombinant multifunctional polypeptides 
  created to exploit a cascade of cellular processes, initiated with membrane receptor recogni-
tion to deliver selective short-range and highly cytotoxic therapeutics to the cell nucleus. This 
research was designed for in vivo concept testing for this drug delivery platform using two 
modular   nanotransporters, one targeted to the α-melanocyte-stimulating hormone (αMSH) 
receptor overexpressed on melanoma cells and the other to the epidermal growth factor (EGF) 
receptor overexpressed on several cancers, including glioblastoma, and head-and-neck and 
breast carcinoma cells.
Methods: In vivo targeting of the modular nanotransporter was determined by immuno-
fluorescence confocal laser scanning microscopy and by accumulation of 125I-labeled modular 
nanotransporters. The in vivo therapeutic effects of the modular nanotransporters were assessed 
by photodynamic therapy studies, given that the cytotoxicity of photosensitizers is critically 
dependent on their delivery to the cell nucleus.
Results: Immunohistochemical analyses of tumor and neighboring normal tissues of mice 
injected with multifunctional nanotransporters demonstrated preferential uptake in tumor 
tissue, particularly in cell nuclei. With 125I-labeled MNT{αMSH}, optimal tumor:muscle and 
tumor:skin ratios of 8:1 and 9.8:1, respectively, were observed 3 hours after injection in B16-
F1 melanoma-bearing mice. Treatment with bacteriochlorin p-MNT{αMSH} yielded 89%–98% 
tumor growth inhibition and a two-fold increase in survival for mice with B16-F1 and Cloudman 
S91 melanomas. Likewise, treatment of A431 human epidermoid carcinoma-bearing mice with 
chlorin e6- MNT{EGF} resulted in 94% tumor growth inhibition compared with free chlorin 
e6, with 75% of animals surviving at 3 months compared with 0% and 20% for untreated and 
free chlorin e6-treated groups, respectively.
Conclusion: The multifunctional nanotransporter approach provides a new in vivo functional 
platform for drug development that could, in principle, be applicable to any combination of cell 
surface receptor and agent (photosensitizers, oligonucleotides, radionuclides) requiring nuclear 
delivery to achieve maximum effectiveness.
Keywords: drug delivery, nanobiotechnology, nanomedicine, cancer therapy, photosensitizers, 
multifunctional nanotransporter
Introduction
The development of therapeutic options for cancer that are both selective and 
  effective presents a major challenge in contemporary biomedicine. Specific deliv-
ery and   binding to malignant cell populations can be achieved by targeting cell 
surface   receptors that are either uniquely expressed or overexpressed on cancer 
cells. A variety of receptor-avid ligands have been evaluated for this purpose, either 
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alone or affixed to nanoparticles,1,2 including antibodies3 
and their fragments,4 other proteins,5 peptides,6 and aptam-
ers.7 After binding to the targeted receptor, the fate of the 
ligand-drug bioconjugate can be either to remain on the 
cell membrane or to be transported into the cytoplasm.8 
However, the efficiency of most therapeutics depends to 
a large extent on their subcellular localization, and for 
many of them, the most vulnerable compartment is the 
nucleus. Furthermore, certain types of therapeutics, such 
as photosensitizers9 and Auger electron emitting radionu-
clides,10 have ranges of action of less than 0.1 µm, which 
is a major advantage for minimizing damage to normal 
tissues adjacent to tumor tissue, but renders their cytotoxic 
effectiveness almost exclusively dependent on achieving 
delivery to the cell nucleus.11
Vehicles that efficiently deliver therapeutic agents 
to their locus in quo in tumor tissue engage receptors on 
the cancer cell surface. Transporting their payload to the 
cell nucleus would be attractive from the standpoint of 
maximizing both the specificity and effectiveness of tumor 
treatment. Our efforts to achieve these goals have been 
focused on nanobiotechnological creation of an artificial 
multifunctional transporting platform, ie, the recombinant 
modular nanotransporter (MNT).12 The MNT is a modular 
polypeptide that can contain four moieties, ie, an internaliz-
able ligand to provide target cell recognition and receptor-
mediated endocytosis by the cell, an endosomolytic module 
to facilitate escape from endosomes, a nuclear localization 
sequence (NLS) motif to allow active transport into the cell 
nucleus via binding to cytoplasmic importins, and a car-
rier domain for efficient attachment of the drug (Figure 1). 
In fact, MNT is an artificially generated detail of the cell 
transport machinery (or a nanodevice, which exploits the 
cell transport machinery) that was designed for cell-specific 
transport into a preassigned cellular compartment (the cell 
nucleus in this case).
Pursuing this strategy,13 we designed, produced, and 
characterized bacterially-expressed MNT comprising 
α-melanocyte-stimulating hormone (αMSH) or epidermal 
growth factor (EGF) for targeting αMSH receptors that are 
overexpressed in melanoma14 or the epidermal growth factor 
receptor (EGFR) that is overexpressed on several cancers, 
including head and neck, breast carcinoma, and glioblas-
toma,15 the optimized nuclear localization sequence from 
SV40 large tumor antigen, the Escherichia coli hemoglobin-
like protein (HMP) as a carrier module, and a translocation 
domain of diphtheria toxin as the endosomolytic amphipathic 
module (DTox). Having demonstrated that MNT could be 
produced and purified efficiently, with retention of function 
of each of the modules, and having shown that every module 
is necessary for the maximum MNT activity,12,16 we next 
evaluated their potential utility as a platform for targeted 
cancer therapy. Conjugation of the photosensitizer chlorin 
e6 to the MNT DTox-HMP-NLS-EGF increased cytotoxic-
ity by a factor of more than 3000 for the EGFR-expressing 
A431 human epidermoid carcinoma cell line compared with 
free chlorin e6.16
Herein, we investigate the in vivo characteristics of 
these MNT, designed to deliver photosensitizers to αMSH 
receptor-expressing and EGFR-expressing tumors. Evidence 
is provided that MNT selectively accumulates in cancer 
cells, with the highest concentration in the cell nuclei. 
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Figure 1 Schematic for construction and delivery of a modular nanotransporter to the nucleus of tumor cells. (A) Modular nanotransporter consisting of four functional 
modules. (B) After intravenous administration, the modular nanotransporter binds via its ligand module to receptors expressed on the surface of tumor cells. (C) The 
modular nanotransporter is delivered to endosomes via receptor-mediated endocytosis, undergoes endosome escape through its endosomolytic module, binds via its nuclear 
localization sequence module to importins in the cytoplasm, and is transported through the nuclear pore to the cell nucleus.
Abbreviations: MNT, modular nanotransporter; NLS, nuclear localization sequence.
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  Importantly, MNT-mediated delivery of photosensitizers 
resulted in more than 90% tumor growth inhibition and sig-
nificantly prolonged survival compared with the free drug, 
while producing few if any side effects.
Materials and methods
Synthesis of MNT
DTox-HMP-NLS-αMSH (70.4 kDa) and DTox-HMP-
NLS-EGF (76.3 kDa) were synthesized and purified as 
described elsewhere.12,16 Briefly, MNT were expressed in 
an E. coli strain M15 carrying plasmid pREP4 according to 
the QIAGEN protocol. The cells were lysed and the MNT 
were purified on Ni-NTA agarose (QIAGEN) according 
to the standard procedure. The MNT were then dialyzed 
against 10 mM sodium phosphate buffer (pH 8) containing 
150 mM NaCl.
Determination of mean hydrodynamic 
diameter of MNT
Particle sizes of DTox-HMP-NLS-EGF (66 µM) in 10 mM 
sodium phosphate buffer (pH 8) containing 150 mM NaCl 
were measured using a ZetaPALS (Brookhaven Instruments, 
Holtsville NY). The instrument was validated with nano-
sphere size standards (polystyrene microspheres in water, 
92 ± 3.7 nm) from Duke Scientific (Palo Alto, CA). The scat-
tered light was detected at a 90° angle. Measurements were 
performed in 40 µL quartz cuvettes at 25°C with count rates 
of about 80 kCps in ten runs of 240 seconds in duration each 
and analyzed by multimodal size distribution analysis.
Determination of MNT size in supported 
lipid bilayers
A Digital Instruments multimode scanning probe microscope 
on a Nanoscope IIIa (Veeco Instruments, Woodbury, NY) 
controller fitted with a J-scanner (165 µm maximum scan 
size) and a tapping mode liquid cell were used to image MNT 
molecules in the lipid bilayer in situ. A piece of mica was 
attached to a 1.6 cm diameter metal disk supplied by Veeco 
and installed in the microscope. The tapping mode liquid cell 
was fitted with inlet and outlet tubing to allow exchange of 
solutions in the cell during imaging. Samples of supported 
unilamellar bilayers were prepared as described earlier.16,17 
Oxide-sharpened silicon nitride V-shaped cantilevers with a 
nominal force constant of 0.06 N/m and a tip with a 10 nm 
curvature radius were used and the forces were minimized 
during the scans. The silicon nitride cantilevers were irradi-
ated with ultraviolet light prior to imaging to remove any 
adventitious organic contaminants. All measurements were 
performed in contact and tapping modes (cantilever drive 
frequencies approximately 9 kHz) at room temperature using 
a tip scan rate of about 2–4 Hz. All images were captured as 
512 × 512 pixels and were flattened and smoothed.
MNT (DTox-HMP-NLS-EGF) caused formation of two 
types of defects in previously intact parts of the bilayer, ie, 
fluctuating holes, partially edged with “heights” and circular 
structures with “ramparts” in the lipid bilayers (  Figure 2B).16,17 
The mean width of these circular structures and their mean 
diameter were measured (Figure 2B). The width was measured 
in the plane of the lipid bilayer. The mean width of the MNT 
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Figure 2 Dimensions of the modular nanotransporter and resulting circular structures. (A) Particle size distribution for a DTox-HMP-NLS-EGF sample (66 µM) in 10 mM 
sodium phosphate buffer (pH 8) containing 150 mM NaCl as measured by dynamic light scattering; the mean hydrodynamic diameter of the modular nanotransporter was 
10.6 ± 0.5 nm. (B) Atomic force microscopy tapping mode height image (100 × 100 nm; z-scale, 4 nm) of egg yolk phosphatidylcholine bilayer recorded in 20 mM HEPES-MES 
buffer with 150 mM NaCl (pH 5.5) containing 5 nM DTox-HMP-NLS-EGF. Mean diameter of circular structures was 43.1 ± 1.2 nm (±SEM) and mean width of these structures 
was 20.8 ± 0.8 nm (±SEM). After correction for a widening of this width caused by final sizes of tips, the mean width of the MNT was 12.5 ± 1.9 nm (±SEM).
Note: Blue and green double arrows represent the diameter and width of the circular structure, respectively.
Abbreviations: MNT, modular nanotransporter; DTox, translocation domain of diphtheria toxin; HMP, Escherichia coli hemoglobin-like protein; NLS, nuclear localization 
sequence; EGF, epidermal growth factor; SEM, standard error of mean.
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molecule was calculated as the mean width of circular struc-
tures with correction for a widening caused by final sizes of the 
tips. This correction was made under the condition r1 $ hc/2 
according to the following formula:  ∆= ⋅⋅ − dr hh cc 8 1 , 
where ∆d, is the widening of apparent width of circular struc-
tures; r1 is the tip curvature radius; and hc is the mean height 
of circular structures. The height of the MNT molecule was 
calculated as the height above the mica surface of the molecules 
observed on the border of fluctuating holes. The mean length of 
the MNT molecule in the lipid bilayer (l) was calculated using 
its mean height (h), mean width (w) and volume (V = πD3/6), 
where D is the mean hydrodynamic diameter. The shape of 
the MNT molecule in lipid bilayer was approximated as an 
ellipsoid, where l = 6V/πhw.
Labeling MNT
DTox-HMP-NLS-αMSH was labeled with  125I by reac-
tion with N-succinimidyl 3-[125I]iodobenzoate18 in 50 mM 
borate buffer and purified on a PD10 gel filtration column 
(  Amersham Biosciences, Piscataway, NJ).
Photosensitizers
Chlorin e6 was obtained from Frontier Scientific (Logan, UT) 
and bacteriochlorin p was kindly provided by the Moscow 
State Academy of Fine Chemical Technologies.
Coupling photosensitizers to MNT
Photosensitizers were coupled to MNT using 1-ethyl-3-
(3-dimethylaminopropyl)-carbodiimide and N-hydroxysuccin-
imide (Sigma, St Louis, MO). Conjugates were purified by gel 
filtration on a Sephadex-G50 (Pharmacia, Philadelphia, PA) 
column in the presence of 1.5 M guanidine hydrochloride or 
by affinity chromatography on Ni-NTA agarose (QIAGEN).
Cell culture
A431 human epidermoid carcinoma cells overexpressing 
EGFR, as well as Cloudman S91 (clone M3) and B16-
F1 murine melanoma cells overexpressing αMSH receptors 
were maintained in Dulbecco’s Modified Eagle Medium 
supplemented with 10% fetal calf serum and 50 μg/mL 
gentamicin. All cell lines were maintained at 37°C in a 
5% CO2 humidified atmosphere. A431 and B16-F1 cells were 
obtained from the American Type Culture Collection and 
passed in the laboratory through less than 30 passages.
Mice
All animal procedures were conducted in accordance with 
procedures approved by the Dierexperimentencommissie 
Faculteit Farmacie/Scheikunde/Biologie, the Gemeen-
schappelijk Dieren Laboratorium, and the Institute of 
Gene Biology.
Delayed-type hypersensitivity reaction
Subcutaneous injection of MNT was performed to evaluate 
delayed-type hypersensitivity reactions (see Supplementary 
data, Materials and methods section).
MNT tissue distribution
Female C57 black/6J mice were inoculated   subcutaneously 
with 1 × 106 B16-F1 murine melanoma cells, and 7–13 days 
later 125I-labeled DTox-HMP-NLS-αMSH ([125I]iodoMNT) 
was injected intravenously in 500 µL of saline with 
  gentamicin 50 µg/mL as follows: 850 µg, specific activity 
6.5 µCi/mg, three mice; 214 µg, specific activity 36 µCi/mg, 
three mice; and 11 µg, specific activity 224 µCi/mg, nine 
mice. Biodistribution was studied for all doses at 3 hours, and 
the 11 µg dose was also evaluated at 70 minutes and 15 hours. 
Mice were anesthetized, euthanized, and their tumors and 
proximal skin and muscle were removed, weighed, and 
counted for 125I (RiaGamma 1271). Tumor-to-normal tissue 
ratios were calculated by dividing the 125I counts per gram 
tumor by the 125I counts per gram normal tissue.
MNT subcellular localization
Female DBA/2 mice bearing Cloudman melanoma S91 
(M3 clone, transfected stably with green fluorescent protein 
[GFP] via copGFP gene) or C57 black female mice bearing 
B16-F1 melanoma were injected intravenously three times 
at 30-minute intervals with 150 mg/kg DTox-HMP-NLS-
αMSH in 0.87–1 mL saline (depending on animal weight) 
with 50 µg/mL gentamicin. Three hours after the last injec-
tion, the mice were sacrificed and perfused with phosphate-
buffered saline. Tumors and surrounding normal tissues were 
removed, embedded in GSV 1 tissue embedding medium 
(Slee Medical GmbH, Mainz, Germany) and snap-frozen in 
liquid nitrogen. The frozen tissue blocks were cut into 10 µm 
sections using a Leica CM1510 cryotome (Leica, Wetzlar, 
Germany), fixed in acetone/methanol (2:3, v/v) mixture for 
10 minutes at -20°C, air-dried, stained with primary rab-
bit anti-MNT antibodies (Ab), followed by staining with 
  secondary goat antirabbit Ab conjugated with Alexa Fluor 
555 (Invitrogen, Carlsbad, CA) then with tertiary donkey 
antigoat Ab conjugated with Alexa Fluor 555, and also with 
DAPI in order to visualize cell nuclei.
Likewise, male Balb/c ByJIco-nu/nu mice bearing A431 
human epidermoid carcinoma xenografts were injected 
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intravenously with 3 mg of chlorin e6-DTox-HMP-NLS-EGF 
conjugate in 750 µL of saline with 50 μg/mL gentamicin; 
a control group did not receive the conjugate. Three hours 
later, the mice in both groups were sacrificed, perfused with 
phosphate-buffered saline, and their tumors and surround-
ing normal tissues were removed. The specimens were 
embedded in Lowicryl K4M, sectioned at 2–3 µm using an 
LKB-3 microtome (LKB, Uppsala, Sweden), and stained as 
described above (tertiary Ab staining omitted).
Subcellular localization was investigated using an LSM 
510 META NLO multiphoton laser scanning microscope 
(Carl Zeiss, Oberkochen, Germany) equipped with a Mai 
Tai broadband mode-locked Ti-sapphire laser (Spectra 
Physics®) with a 63× or 40× objective lens, NA 1.4 and 1.3, 
respectively. Alexa Fluor 555 fluorescence was excited with 
a He-Ne laser (543 nm); DAPI fluorescence was two-photon 
excited with a Ti-sapphire laser (800 nm), and GFP fluores-
cence was excited with an Ar laser (458 nm). When evalu-
ating A431 specimens, Alexa Fluor 555 fluorescence was 
separated from autofluorescence by analysis of fluorescence 
spectra within the 564–704 nm range using the microscope 
META system and a linear unmixing standard procedure. To 
calculate the percentage of fields with specific MNT signal in 
tumor and neighboring skin cells, nuclei and cytoplasm were 
defined by DAPI fluorescence and transmitted light images, 
respectively. At least 89 fields of approximately the same 
area were used for each point and the average Alexa Fluor 
555 signal intensity was measured in each field. A signal 
was considered to be specific if it exceeded the intensity of 
fluorescence in 95% of the control field area (tissue sections 
processed in the same manner but obtained from control mice 
not receiving MNT).
In vivo efficacy
B16-F1 melanoma
A total of 5 × 105 B16-F1 melanoma cells in 10 µL Dulbecco’s 
Modified Eagle Medium were inoculated subcutaneously 
into the depilated right hind flanks of female C57 black/6J 
mice. Four days later, mice were injected intravenously 
with either 27 µg of bacteriochlorin p coupled with 1 mg 
DTox-HMP-NLS-αMSH in 500 µL of saline containing 
50 µg/mL gentamicin (n = 5; MNT-bacteriochlorin group) 
or 27 µg of bacteriochlorin p in 500 µL of saline contain-
ing 50 µg/mL gentamicin (n = 5; bacteriochlorin group); 
nine untreated mice served as controls. After 3 hours, the 
tumors were illuminated with a 400 W lamp (ELT) through 
an interference filter (transmittance maximum at 761 nm), 
380 mW/cm2 fluence rate, and 360 J/cm2 illumination 
dose. This injection/  illumination scheme was repeated on 
days 6, 8, 11, and 13 after melanoma cell inoculation.
Cloudman S91 melanoma
A total of 5 × 105 Cloudman S91 (clone M3) melanoma cells 
in 10 µL of Hanks’ solution were inoculated subcutaneously 
into the depilated right hind flanks of female DBA/2 mice. 
Three days later, the mice were injected intravenously with 
either 19 µg of bacteriochlorin p coupled with 1 mg of DTox-
HMP-NLS-αMSH in 230 µL of saline containing 50 µg/mL 
gentamicin (n = 5, MNT-bacteriochlorin group) or 19 µg of 
bacteriochlorin p in 230 µL of saline containing 50 µg/mL 
gentamicin (n = 4; bacteriochlorin group); eight untreated 
mice served as controls. After 3 hours, tumors were illumi-
nated with a 400 W lamp (ELT) through an interference filter 
(transmittance maximum at 761 nm), 38 mW/cm2 fluence 
rate, and 36 J/cm2 illumination dose. On days 4, 5, 6, and 7 
after tumor cell inoculation, the MNT-bacteriochlorin group 
received 24 µg of bacteriochlorin p coupled with 1.2 mg of 
DTox-HMP-NLS-αMSH in 280 µL of saline containing 
50 µg/mL gentamicin and the bacteriochlorin group received 
24 µg of bacteriochlorin p in 280 µL of saline containing 
50 µg/mL gentamicin; 3 hours later, tumors were illumi-
nated at 761 nm, 380 mW/cm2 fluence rate, and 360 J/cm2 
illumination dose.
Human A431 epidermoid carcinoma
A total of 1 × 106 A431 cells in 10 µL of phosphate-buffered 
saline were inoculated subcutaneously into the right hind 
flanks of male Balb/c ByJIco-nu/nu mice. On days 3, 6, 8, 
11, 14, and 20, mice were injected intravenously with either 
44 µg chlorin e6 coupled with 3 mg DTox-HMP-NLS-EGF 
in 750 µL of saline containing 50 µg/mL gentamicin (n = 8; 
MNT-chlorin group) or 44 µg of chlorin e6 in 500 µL of 
saline containing 50 µg/mL gentamicin (n = 10; chlorin 
group); 11 untreated mice comprised the control group. 
After 3 hours, the tumors were illuminated with a laser 
beam (Biolitec AG, Jena, Germany) at 652 nm (80 mW/cm2 
fluence rate and 48 J/cm2 illumination dose for the first and 
second treatments; 100 mW/cm2 fluence rate and 60 J/cm2 
illumination dose for later treatments).
Tumor response
Percentage of tumor growth inhibition was calculated as a 
normalized difference between the change in control and 
treated tumor volumes on the last day that all animals were 
alive in all treatment and control groups.19 Additional details 
are provided in the Supplementary data.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
471
Working platform for targeted drug deliveryInternational Journal of Nanomedicine 2012:7
Statistical analysis
Error bars represent the mean value ± standard error of 
the mean (SEM). Statistical significance for tumor growth 
inhibition and survival studies was determined by the Mann–
Whitney test; other analyses used Student’s t-test. P , 0.05 
were considered to be statistically significant.
Results
MNT design
Small-sized (mean hydrodynamic diameter 10.6 ± 0.5 nm, 
Figure 2A) specific multifunctional MNT demonstrated 
excellent results in enhancement of photodynamic effects 
of photosensitizers on cancer cell lines in vitro, but their 
action on tumors was not investigated up to this time. Such 
an approach has advantages when precise delivery of a rela-
tively small number of molecules per cell is sufficient for 
a therapeutic effect. In this sense, use of photosensitizers 
is a convenient way for testing the approach in vivo. MNT 
DTox-HMP-NLS-αMSH and DTox-HMP-NLS-EGF were 
designed to facilitate four subcellular routing events, ie, 
receptor binding, endocytosis, endosomal escape, and nuclear 
import, by combining four functional modules from their 
N-terminal to C-terminal ends (Figure 1). Functionality of 
all these modules was checked as previously described12,16,17 
and confirmed. MNT were capable of specific interaction with 
targeted receptors, being overexpressed on tumor cells, and 
subsequent receptor-mediated endocytosis.12,16
At endosomal pH, MNT embedded into the lipid 
bilayer and could self-assemble into circular structures16,17 
(  Figure 2B). Analyzing these specific structures, we estimated 
the mean height, width, and length of the MNT molecule as 
5.3 ± 0.4, 9.0 ± 0.9, and 12.5 ± 1.9 nm (±SEM), respectively. 
On the basis of these dimensions and a mean diameter of 
the circular structures of 43.1 ± 1.2 nm, the mean number of 
MNT molecules in these circular structures was calculated 
to be 11 ± 2. These structures formed pores,16,17 permitting 
escape of MNT into the hyaloplasm,12 where they can interact 
with importins. Finally, MNT interacted with the α/β importin 
heterodimer, mediating nuclear import with an affinity very 
close to that for the same NLS as a free oligopeptide.12,16
Murine melanomas (Cloudman S91, clone M3, and 
B16-F1 cell lines) as well as human epidermoid carcinoma 
A431 cells were chosen for treatment of experimental tumors 
overexpressing the αMSH receptor and EGFR, respectively. 
MNT and their photosensitizer conjugates retained bioactiv-
ity after storage at 4°C or even after long-term storage in 
freeze-dried form at room temperature (see Supplementary 
data, Figures S1 and S2).
MNT toxicity and immunogenicity
C57 black/6J mice (n = 3, 4-week observation) tolerated 
the highest achievable intravenous dose of DTox-HMP-
NLS-αMSH (7.5 mg), slowly injected in 1.5 mL of saline 
with 50 µg/mL gentamicin; higher MNT doses could not 
be evaluated because of limitations in MNT solubility. C57 
black/6J (n = 5, 2-week observation) and Balb/c ByJIco-nu/
nu (n = 8, 4-week observation) mice also tolerated multiple 
intravenous injections of 4 × 2 mg DTox-HMP-NLS-αMSH 
and 6 × 3 mg DTox-HMP-NLS-EGF, respectively, with time 
intervals of 2–3 days between doses. Intravenous adminis-
tration of DTox-HMP-NLS-EGF to C57 black/6J at a dose 
of 4 mg per mouse did not lead to significant changes in 
behavior or macroscopic organ changes, when compared 
with animals injected with the same volume of saline. In 
the microscopic study, the only significant change relative 
to the control group was a 30% reduction in the number of 
binuclear hepatocytes, which may indicate a decrease in liver 
proliferative capacity (data obtained in collaboration with 
Zenkova et al, manuscript in preparation). These data show 
that MNT are not toxic to mice when administered either as 
a single injection at the maximum achievable dose or when 
administered in multiple dose regimens.
Delayed-type hypersensitivity reactions are often used 
as a correlate of immune response to administered polypep-
tides.20 MNT administration induced slight delayed-type 
hypersensitivity in C57 black/6J mice injected with DTox-
HMP-NLS-αMSH (5.4%), with the difference between 
experimental and control groups not being statistically 
significant. Generally, an increase over the control group of 
about 20% or more is considered to indicate an immunogenic 
response,21 suggesting a low degree of immunogenicity for 
this MNT.
In vivo targeting evaluated  
with 125I-labeled MNT
DTox-HMP-NLS-αMSH was labeled with  125I using the 
N-succinimidyl 3-[125I]iodobenzoate reagent, a method that 
has been shown to decrease in vivo deiodination by up to 
two orders of magnitude compared with conventional electro-
philic methods.18 The 125I-labeled DTox-HMP-NLS-αMSH 
was injected intravenously into C57 black/6J mice bearing 
mouse melanoma tumors derived from B16-F1 cells which 
express about 10,000 αMSH receptors per cell,22 and the 
biodistribution of activity in different tissues was measured 
(see Supplementary data, Figure S3). The ratio of 125I   activity 
in tumor tissue relative to that in skin and muscle was chosen 
as a metric for evaluating in vivo targeting because these 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
472
Slastnikova et alInternational Journal of Nanomedicine 2012:7
tissues are in proximity to melanoma and their collateral 
damage from photodynamic therapy should be avoided.
As shown in Figure 3, the selectivity of  125I-labeled 
DTox-HMP-NLS-αMSH retention generally increases with 
time. Tumor selectivity tends to be higher with doses of 
MNT $ 200 µg, than with 11 µg. The optimal dose seen for 
targeting at 3 hours was 214 µg for tumor:skin (9.8 ± 1.8) 
and 850 µg for tumor:muscle (13.4 ± 1.7) with a slightly 
higher tumor:muscle ratio than tumor:skin ratio, presumably 
reflecting the presence of melanocytes which express αMSH 
receptors in normal skin.23 It is worth noting that the maxi-
mum tumor:skin ratio determined for MNT in this work is 
3–8 times higher than those reported for free photosensitizers 
in this murine melanoma model.24–26
Based on these data demonstrating that tumor selectivity 
generally increases (Figure 3) while tumor accumulation 
rapidly decreases with time (dropping by more than 90% 
from 3 to 15 hours, see Supplementary data, Figure S4), we 
had chosen a time interval of 3 hours as a “happy medium” 
of significant tumor accumulation and selectivity rates for 
subsequent distribution and therapeutic experiments.
In vivo targeting evaluated by 
immunofluorescence microscopy
DTox-HMP-NLS-αMSH was injected intravenously into 
DBA/2 mice bearing Cloudman S91 melanoma, which 
express about 5000 αMSH receptors per cell22 and into C57 
black/6J mice bearing B16-F1 mouse melanoma expressing 
about 10,000 αMSH receptors per cell.22 Preferential tumor 
accumulation of MNT was observed at 3 hours after injection, 
which was distinguished from surrounding nontumor tissue 
by GFP fluorescence of transfected Cloudman S91 mela-
noma cells (Figure 4A–D). Moreover, comparison of MNT to   
DAPI staining suggested that a considerable fraction of MNT 
accumulation in both B16-F1 and Cloudman S91 melanoma 
cells occurred in the cell nuclei (Figure 5D–I). The percentage 
of fields exhibiting an MNT signal in nuclei and cytoplasm of 
tumor and proximal skin cells was also evaluated. As shown 
in Figure 4E, more than 80% and nearly 100% of fields in 
melanoma had an MNT signal in the nuclei and cytoplasm, 
respectively, compared with values of ,40% in skin. Because 
MNT internalization and transport to nuclei via cytoplasm is 
going on from outside continuously, we can only observe a 
“  snapshot” of intracellular distribution of the MNT, with a sig-
nificant part caught on its way (eg, in the cytoplasm) to the target 
compartment. Similar results were obtained after intravenous 
injection of DTox-HMP-NLS-EGF into Balb/c ByJIco-nu/nu 
mice bearing EGFR-expressing human epidermoid carcinoma 
A431 xenografts, ie, accumulation of MNT in tumor cells with 
evidence for localization within the cell nuclei (Figure 5A–C). 
These experiments confirm that MNT can be designed to 
undergo transport from the blood pool to the intended subcel-
lular target in receptor-expressing tumor cells in vivo.
In vivo MNT antitumor efficacy
In order to evaluate the potential utility of MNT for enhancing 
the therapeutic efficacy of a drug that requires   localization 
within the cell nucleus to be effective, photodynamic 
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Figure 3 Tumor-to-tissue ratios of 125I after intravenous injection of 125I-labeled DTox-HMP-NLS-αMSH in B16-F1 melanoma-bearing C57 black/6J mice. (A) Effect of time, 
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Note: Bars represent the mean ± SEM (n = 3).
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therapy studies were performed in three different subcuta-
neous murine tumor models, with therapy initiated 3 hours 
after injection of the photosensitizer. The first experiment 
was performed in C57 black/6J mice with B16-F1 melanoma. 
An 89% inhibition of tumor growth was observed with the 
bacteriochlorin p-DTox-HMP-NLS-αMSH conjugate, while 
no significant effect was seen with free bacteriochlorin p 
(Figure 6A). Median survival for mice receiving the photo-
sensitizer-MNT conjugate was 32.0 ± 1.3 days, compared 
with 17.0 ± 1.5 days for the control group and 20.0 ± 5.5 days 
for the bacteriochlorin p group (Figure 6B). The difference 
in survival between photosensitizer-MNT and each of two 
control groups was significant (P , 0.01). The second experi-
ment utilized DBA/2 mice with Cloudman S91 melanoma, 
and a 98% inhibition in tumor growth was observed with 
the bacteriochlorin p-DTox-HMP-NLS-αMSH conjugate 
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Figure 4 Immunofluorescence analysis of in vivo distribution in tumor and neighboring 
tissue, and subcellular localization of MNT 3 hours after intravenous injection in mice. 
10 µm tissue sections from DBA/2 mice bearing murine Cloudman melanoma S91 
transfected with green fluorescent protein receiving DTox-HMP-NLS-αMSH. (A–D) 
Tumor and surrounding tissue section (40× objective lens). (A) Alexa Fluor 555 staining 
for MNT (red); (B) green fluorescent protein from tumor cells (green); (C) DAPI 
staining of cell nuclei (blue); (D) overlay of A, B, and C. (E) Percentage of fields (±SEM) 
with specific MNT signal in nuclei and cytoplasm of tumor and neighboring skin cells.
Notes: Bars represent the mean ± SEM (n $ 89); scale bar, 20 µm.
Abbreviations: MNT, modular nanotransporter; DTox, translocation domain of 
diphtheria  toxin;  HMP,  the  Escherichia  coli  hemoglobin-like  protein;  NLS,  nuclear 
localization  sequence;  αMSH,  α-melanocyte  stimulating  hormone;  SEM,  standard 
error of mean; DAPI, 4′,6-diamidino-2-phenylindole.
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Figure  5  Immunofluorescence  analysis  of  in  vivo  subcellular  localization  of 
MNT 3 hours after intravenous injection in mice. (A–C) 2–3 µm tumor section 
(63×  objective  lens)  from  Balb/c  ByJIco-nu/nu  mouse  bearing  human  A431 
epidermoid carcinoma 3 hours after intravenous injection of chlorin e6-DTox-HMP-
NLS-EGF, (A′–C′) the same, but from the control mouse that was injected with 
saline. (D–F) 10 µm tumor section (63× objective lens) from C57 black/6J mice 
bearing murine B16-F1 melanoma injected with DTox-HMP-NLS-αMSH, (D′–F′) 
the same, but from the control mouse that was injected with saline. (G–I) 10 µm 
tumor section (63× objective lens) from DBA/2 mice bearing murine Cloudman 
melanoma S91 injected with DTox-HMP-NLS-αMSH, (G′–I′) the same, but from 
the control mouse that was injected with saline. (A), (A′), (D), (D′), (G), (G′) DAPI 
staining of cell nuclei (blue); (B), (B′), (E), (E′), (H), (H′) Alexa Fluor 555 staining 
for MNT (red); (C), (C′), (F), (F′), (I), (I′) overlay of cell nuclei fluorescence (blue) 
and MNT fluorescence (red). Scale bar 5 µm for (A–F) and for (A′–F′); scale bar   
10 µm for (G–I) and for (G′–I′).
Abbreviations:  MNT,  modular  nanotransporter;  DTox,  translocation  domain 
of diphtheria toxin; HMP, the Escherichia coli hemoglobin-like protein; NLS, nuclear 
localization sequence; EGF, epidermal growth factor; αMSH, α-melanocyte stimulating 
hormone; SEM, standard error of mean; DAPI, 4′,6-diamidino-2-phenylindole.
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Figure 6 Comparative efficacy of photodynamic therapy with bacteriochlorin p conjugated with DTox-HMP-NLS-αMSH MNT and free bacteriochlorin p. (A–B) C57 
black/6J mice with subcutaneous B16-F1 murine melanoma. (A) Tumor growth, mean ± SEM; average tumor volumes are shown up to the last day when all animals were 
alive. (B) Kaplan-Meier survival curve. (C–D) DBA/2 mice with subcutaneous Cloudman S91 murine melanoma. (C) Tumor growth, mean ± SEM; average tumor volumes 
are shown up to the last day when all animals were alive. (D) Kaplan-Meier survival curve.
Notes: Arrows indicate injection and illumination cycles; bars represent the mean ± SEM.
Abbreviations: MNT, modular nanotransporter; DTox, translocation domain of diphtheria toxin; HMP, the Escherichia coli hemoglobin-like protein; NLS, nuclear localization 
sequence; αMSH, α-melanocyte stimulating hormone; SEM, standard error of the mean.
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Figure 7 Photodynamic therapy with chlorin e6 conjugated with DTox-HMP-NLS-EGF MNT inhibits A431 human epidermoid carcinoma growth and enhances survival of 
tumor-bearing Balb/c ByJIco-nu/nu mice compared with free chlorin e6. (A) A431 tumor growth, mean ± SEM; average tumor volumes are shown up to the last day when all 
animals were alive. (B) Kaplan-Meier survival curve.
Notes: Arrows indicate injection and illumination cycles; bars represent the mean ± SEM.
Abbreviations: MNT, modular nanotransporter; DTox, translocation domain of diphtheria toxin; HMP, Escherichia coli hemoglobin-like protein; NLS, nuclear localization 
sequence; EGF, epidermal growth factor; SEM, standard error of mean.
relative to controls (93% relative to free photosensitizers, 
Figure 6C). Median survival for mice receiving the photosen-
sitizer-MNT conjugate was 56.0 ± 18.6 days compared with 
21.0 ± 0.7 days for the control group and 31.0 ± 1.3 days for 
the bacteriochlorin p group (Figure 6D). The third experi-
ment was performed with chlorin e6-DTox-HMP-NLS-EGF 
in Balb/c ByJIco-nu/nu mice with A431 human epidermoid 
carcinoma xenografts. A 98% inhibition in tumor growth 
was observed with the chlorin e6-DTox-HMP-NLS-EGF 
conjugate relative to controls (94% relative to free photosen-
sitizers, Figure 7A). Median survival for mice in the control 
group was 20.0 ± 0.4 days, with all animals succumbing by 
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24 days (Figure 7B). In contrast, 75% of animals remained 
alive at the end of the 92-day observation period in the chlorin 
e6-DTox-HMP-NLS-EGF group compared with 20% in the 
chlorin e6 group.
Discussion
Multicomponent systems consisting of modified biological 
molecules or their parts,27 biological particles or their parts,28 
and even subcellular structures29 are often used as delivery 
systems. In this study, we describe the in vivo working 
polypeptide-based, multifunctional platform for targeted 
delivery of short-range highly cytotoxic therapeutics to the 
most vulnerable compartment of the tumor cell. We demon-
strate that selective accumulation in tumors, with preferential 
accumulation in cancer cell nuclei but not in adjacent normal 
tissue, enhances the therapeutic efficacy of photosensitiz-
ers, a type of drug that requires localization within the cell 
nucleus to be effective. In designing a nanosized multifunc-
tional vehicle for achieving efficient delivery to cell nuclei 
in cancer cells, the first objective was to optimize delivery 
to the tumor and the second was to facilitate intracellular 
transport to the nucleus. With regard to the former, the 
tumor uptake of, eg, nanoparticles, exploits the presence of 
200–1200 nm pores present in tumor vascular endothelium30 
via the enhanced permeability and retention effect. However, 
this generally occurs at the expense of being able to improve 
specificity through the addition of a receptor-addressable 
targeting element.31–34 Instead, given that tumor permeability 
and extravasation increases with decreasing molecular size, 
we decided to assemble an artificial multifunctional device 
genetically with a controllable molecular weight rather 
than utilize a particle scaffold with multiple functional ele-
ments decorating its surface. One cannot exclude the pos-
sibility that the enhanced permeability and retention effect 
can play a role when MNT-photosensitizer conjugates are 
administered intravenously. However, it should be noted 
that the enhanced permeability and retention effect can also 
be observed with free photosensitizers; more than 90% of 
them are immediately taken up by different blood proteins 
and lipoproteins, mainly by low-density lipoproteins, high-
density lipoproteins, and albumin.35 In tumor tissue, where 
extracellular pH is lower than that of normal tissue, chlorin 
e6 binds to low-density lipoproteins which are considered 
to be effective photosensitizer delivery vehicles,36 and sig-
nificantly better than at neutral pH.37,38 Thus, the injected 
photosensitizers exist in blood mainly in a protein-bound 
state and their behavior is governed37 by the macromolecules 
and macromolecular complexes which bind them. It has been 
shown that the enhanced permeability and retention effect 
can be observed with macromolecules having an apparent 
molecular size larger than 40–800 kDa.39 In comparison, the 
molecular weight of our MNT is approximately 70 kDa, and 
that of low-density lipoprotein is about 3000 kDa.40 Leunig 
et al,41 who investigated tumor accumulation of different 
porphyrin-like photosensitizers, showed that the enhanced 
permeability and retention effect appears to be the most 
probable reason for the tumor selectivity of this type of pho-
tosensitizer. Therefore, qualitatively, free photosensitizer in 
tumor vessels and photosensitizer transported by MNT may 
be considered as similar in terms of enhanced permeability 
and retention effect, and perhaps even more favorable for 
the free photosensitizer.
Selective delivery of a drug to the cell nucleus is depen-
dent on at least three design elements, ie, a NLS, a size com-
patible with passage through pores in the nuclear membrane, 
and a means of achieving specific binding to the targeted 
cell population. A variety of NLS, including the one used 
in this study, have been shown to deliver drugs efficiently 
to the cell nucleus via binding to importins present in the 
cytoplasm.42 However, even after binding of a molecule to 
NLS, the size of the openings in the nuclear pore complex 
only increases from 8–10 nm to about 40 nm,43,44 restricting 
nuclear entry to larger carrier systems. Another limitation 
of NLS-mediated delivery is that it lacks tumor specificity. 
One approach that has been investigated to circumvent this 
problem is to couple multiple NLS to internalizing antibod-
ies.45,46 Although NLS conjugation was shown to enhance 
nuclear localization, the majority of the activity was found in 
other cellular   compartments. A possible contributing factor 
to these observations is sequestration of the NLS-modified 
antibody in endosomes after receptor-mediated endocytosis, 
which could lead to proteolytic degradation of the conjugate 
and/or prevent significant interaction with nuclear transport 
receptors present in the cytoplasm.
For this reason, we believe that an important design 
element of these MNT is the provision of an endosome 
escape pathway, thereby increasing the probability of NLS 
contact with cytoplasmic importins and facilitating nuclear 
  translocation. The translocation domain of DTox was selected 
for this purpose and previous studies have shown that MNT 
containing the DTox sequence resulted in the creation of 
pores in lipid bilayers at endosomal/lysosomal pH.16,17
In vitro, it is possible to separate the two processes 
involved,16 ie, MNT penetration into the cell cytoplasm 
and subsequent MNT nuclear accumulation in the nuclei. 
The cells can be additionally incubated without MNT after 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
476
Slastnikova et alInternational Journal of Nanomedicine 2012:7
incubation with MNT, thus permitting cytoplasmic MNT to 
enter into the nuclei. However, such a method cannot be used 
in vivo. One needs to make frozen sections in the situation 
where the MNT has gone from the blood pool and intercel-
lular space to the target cells, where the MNT is presumed 
to pass from the cell membrane to the cytoplasm, and finally 
undergo translocation to the cell nuclei. Moreover, one must 
utilize a method with sufficient sensitivity to detect dimin-
ishing quantities of the MNT. Fortunately, such a favorable 
concurrence of circumstances can be seen in Figure 5A–C, 
which depicts predominantly nuclear MNT accumulation. 
In other cases (Figure 5D–F, Figure 5G–I), we obtained 
images showing that MNT is in the nuclei and also in the 
cytoplasm. Nevertheless, all the images are consistent with 
nuclear targeting of MNT.
Perhaps the most relevant metric for evaluating the poten-
tial utility of MNT for transport of a drug from the blood 
pool to the nuclei of target cell populations is to determine 
the effect of MNT conjugation on the therapeutic efficacy 
of a drug that is cytotoxic only when localized in the cell 
nucleus. Although Auger electron emitting radionuclides 
ultimately might be the best method for eventual clinical 
application of MNT, they also emit other radiation with 
multicellular ranges. Instead, we evaluated MNT in the con-
text of photodynamic therapy because the cytotoxic reactive 
oxygen species generated upon photoactivation have a radius 
of action of less than 0.02 µm and their effects in tumor 
tissue can be switched on and off nearly instantaneously 
with light of an appropriate wavelength.47 A time interval 
of 3 hours between photosensitizer-MNT or photosensitizer 
administration and tumor illumination was selected on the 
basis of previous studies using chlorin e6 and its derivatives 
for photodynamic therapy48 and our data on tumor-specific 
accumulation kinetics of MNT. In the three in vivo efficacy 
experiments, the nature of the tumor, receptor target, pho-
tosensitizer and MNT varied, and differences in therapeutic 
effectiveness of the photosensitizer-MNT (and also the free 
photosensitizer) were observed.
Treatment of melanoma by photodynamic therapy is 
hindered substantially by almost complete absorption of 
light by melanin.49 For this reason, the therapeutic efficacy 
of DTox-HMP-NLS-αMSH in the two murine melanoma 
models in tandem with bacteriochlorin p, a photosensitizer 
with an absorption peak at a wavelength (761 nm) where light 
penetration is better, was estimated. Furthermore, in vitro 
studies have shown that coupling this MNT to bacteriochlorin 
p resulted in a more than 200-fold enhancement in cytotoxic-
ity compared with free photosensitizer.12   Particularly given 
the difficulties inherent in photodynamic therapy for 
melanoma, the two-fold increase in median survival and 
significant inhibition in tumor growth obtained with the 
bacteriochlorin p-DTox-HMP-NLS-αMSH conjugate in both 
the B16-F1 and Cloudman S91 models is very   encouraging. 
Consistent with its less pigmented nature, offering the pos-
sibility of higher light penetration, longer median survivals 
for photosensitizer-MNT (and free photosensitizer) were 
seen in animals with Cloudman S91 melanoma. However, 
it should be noted that the average number of αMSH recep-
tors on B16-F1 cells in vitro is about twice that reported for 
Cloudman S91 cells.22
Photodynamic therapy was also performed with chlorin 
e6-DTox-HMP-NLS-EGF in athymic mice with A431 human 
epidermoid carcinoma xenografts in order to evaluate the 
therapeutic response obtainable with an MNT containing a 
different ligand module and in a setting less compromised 
by light absorption. The A431 xenograft is not pigmented 
and this property permits usage of photosensitizers absorb-
ing light at a shorter wavelength (664 nm for chlorin e6 in 
phosphate-buffered saline) than bacteriochlorin p. Moreover, 
the average number of EGFR on the A431 cell line (about 
106) is at least 100 times higher than the number of αMSH 
receptors on either the B16-F1 or Cloudman S91 melanoma 
cell lines, which could facilitate selective MNT binding 
to tumor. Finally, in vitro studies have shown that chlorin 
e6-DTox-HMP-NLS-EGF had a 3000 times higher efficacy 
compared with free photosensitizer;16 likewise, DTox-HMP-
NLS-EGF labeled with the α-particle emitter 211At was sig-
nificantly more cytotoxic than free 211At.50 Consistent with 
being the most favorable setting studied for receptor-targeted 
photodynamic therapy, the results obtained in terms of tumor 
growth delay and survival prolongation were the most strik-
ing, with 75% of animals receiving chlorin e6-DTox-HMP-
NLS-EGF remaining without growing tumor at the end of 
the 3-month observation period.
Conclusion
In summary, this study provides the first in vivo evidence 
that MNT can selectively deliver drugs to the nuclei of tumor 
cells expressing a targeted receptor. MNT can improve speci-
ficity of drugs that ultimately can result in decreased side 
effects for patients, which is the main advantage and goal 
of nanomedicine.51 Moreover, delivery of drugs requiring 
nuclear transport to have a meaningful cytotoxic effect can 
be enhanced significantly through MNT-mediated delivery 
in vivo. In addition, preliminary studies suggest that MNT 
possess low toxicity and immunogenicity, as well as the 
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practical advantages of being a nanoscale delivery system, 
including ease of production, long-term stability, and unifor-
mity of physiochemical properties. Most of the “… desired 
characteristics for a nanoparticle drug delivery platform …”52 
can be ascribed to MNT, ie, small size, stability under 
physiological conditions, inherently nontoxic materials and 
degradation products, moderate lifetime in the circulatory 
system (half-life about 45 minutes in mice for MNT similar 
to those described here; our unpublished data), a trigger 
mechanism for release into the hyaloplasm from acidifying 
endosomes, and specific cellular and subcellular targeting. 
Further, compared with most nanoscale delivery systems, 
MNT possess the essential combination of three functional 
modules, designed to provide step-by-step specific delivery 
from the surface of the target cell to its nucleus. As already 
mentioned, NLS, which is necessary to achieve entry of 
a particle/macromolecule into the interphase nucleus, can 
increase the size of the opening in the nuclear pore complex 
from only 8–10 nm to about 40 nm, which restricts nuclear 
entry of larger carrier systems, including most liposomes 
and nanoparticles. This is one of the reasons for using MNT 
to achieve intranuclear delivery of drugs. Also, among the 
other potential advantages of MNT, one can mention their 
uniformity in size and composition. Finally, MNT offer the 
possibility of long-term storage, favorably distinguishing 
MNT from those nanoparticle systems that require prepara-
tion a relatively short time prior to use.53,54 Finally, because 
of the modular nature of MNT design, one could envisage 
utilizing this platform to generate personalized therapeutics 
by tailoring the ligand and drug profiles to the characteristics 
of individual patients.
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Supplementary data
Evaluation of MNT functionality  
after freeze-drying
Stability and convenience are important factors in evaluat-
ing the potential utility of a nanosystem as a platform for 
the development of therapeutics. To address this issue, 
the functional properties of the modular nanotransporter 
(MNT) and the MNT-photosensitizer conjugates described 
in this study have been investigated after being subjected to 
freeze-drying. The MNT, comprising epidermal growth fac-
tor (EGF) for targeting the epidermal growth factor receptor 
(EGFR) that is overexpressed on several cancers, including 
head and neck, breast carcinoma, and glioblastoma, the opti-
mized nuclear localization sequence from SV40 large tumor 
antigen (NLS), the Escherichia coli hemoglobin-like protein 
(HMP) as a carrier module, and a translocation domain of 
diphtheria toxin as the endosomolytic amphipathic module 
(DTox) (DTox-HMP-NLS-EGF) samples were snap-frozen in 
liquid nitrogen in phosphate-buffered saline (150 mM NaCl, 
10 mM sodium phosphate, pH 8) and freeze-dried. There-
after, the preparations were reconstituted by the addition of 
deionized water. This procedure did not affect the solubility 
of the MNT and its affinity for EGF receptors on A431 cells 
(Figure S1A). Sixteen months of storage of freeze-dried 
DTox-HMP-NLS-EGF under different conditions did not 
significantly change its binding affinity for the EGF receptor 
on A431 cells (Figure S1B).
In vivo 125I-labeled MNT tissue 
distribution
As an initial investigation of the feasibility of utilizing 
MNT for targeted delivery of drugs such as photosensitiz-
ers or radionuclides emitting short range radiation to tumors 
in vivo, the whole body distribution of 125I-labeled MNT was 
determined in mice bearing subcutaneous B16-F1 melanoma 
tumors (Figure S3). However, our primary focus was on 
measuring tumor/skin and tumor/muscle ratios because of 
the potential utility of this α-MSH receptor-targeted MNT 
for treatment of melanoma by photodynamic therapy.
It is worth noting that even though the level of α-MSH 
receptors expressed on B16-F1 cells (about 10,000 recep-
tors per cell4) is relatively low compared, for example, 
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A
Figure S1 Competition for binding to A431 cells with [125I]iodoEGF for DTox-HMP-NLS-EGF. (A) Influence of freeze-drying on binding DTox-HMP-NLS-EGF with 
A431 cells. Green triangles and line are freshly purified DTox-HMP-NLS-EGF (the association constant, Ka = (0.054 ± 0.050) × 109 L/mol), dark blue rhombi and fitted line 
are freeze-dried and reconstituted preparations (Ka = (0.046 ± 0.050) × 109 L/mol). (B) Influence of different storage conditions for 16 months on binding of freeze-dried 
DTox-HMP-NLS-EGF to A431 cells. Green triangles and fitted line are DTox-HMP-NLS-EGF after the storage at 2°C (Ka = (0.074 ± 0.011) × 109 L/mol); orange triangles 
and fitted line are DTox-HMP-NLS-EGF after the storage at room temperature (Ka = (0.059 ± 0.010) × 109 L/mol); light blue triangles and fitted line are DTox-HMP-NLS-
EGF after the storage at -70°C (Ka = (0.037 ± 0.005) × 109 L/mol). Human recombinant EGF was labeled with 125I using Iodogen to an initial specific activity of 410 Ci/mmol 
and purified by gel filtration over a PD-10 column (GE Healthcare). Competition experiments were carried out in 48-well plates with 2 nM of [125I]iodoEGF and incremental 
concentrations of MNT in 200 µL of Dulbecco’s Modified Eagle Medium supplemented with 20 mM HEPES and 20 mg/mL bovine serum albumin, pH 7.3. The plates were 
incubated at 4°C for 20 hours, washed three times with Hanks’ solution containing bovine serum albumin, then cells were lysed with 0.5 M NaOH, and the radioactivity in 
the cell lysates was measured with a gamma counter. The affinity constant of [125I]iodoEGF to EGF receptors ((0.149 ± 0.015) × 109 L/mol) was assessed after experiments 
with binding of incrementing concentrations of the labeled EGF using SigmaPlot 10 software. Nonspecific binding, measured by coincubation with 1 µM non-labeled EGF, 
did not exceed 5% of total binding. The association constants for ligand binding were calculated by nonlinear regression of binding data1 with a one-site binding model. All 
experiments were carried out in triplicate, and error bars represent the SEM. The phototoxicity of DTox-HMP-NLS-EGF-bacteriochlorin p for A431 cells was not affected 
by freeze-drying/reconstitution (Figure S2). The EC50 determined for the MNT-photosensitizer conjugate before and after freeze drying/reconstitution were 3.4 ± 0.5 nM 
and 4.2 ± 1.6 nM, respectively (P . 0.7). Incubation of A431 cells with MNT DTox-HMP-NLS-EGF without subsequent irradiation did not affect cell growth up to MNT 
concentrations sufficient for complete photodynamic mediated cell death. Free photosensitizer (chlorin e6) did not affect cell viability at the irradiation doses used for this 
particular experiment (270 kJ/cm2), as well as up to more than 500 kJ/cm2.3
Abbreviations: MNT, modular nanotransporter; DTox, translocation domain of diphtheria toxin; HMP, Escherichia coli hemoglobin-like protein; NLS, nuclear localization 
sequence; EGF, epidermal growth factor; SEM, standard error of the mean.
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with the 340,000 sites/per cell reported for high molecular 
weight melanoma-associated antigen5 (HMW-MAA), the 
tumor-targeting properties of MNT were comparable with 
those for anti-HMW-MAA monoclonal antibody-based 
constructs.5,6 Moreover, due to the modular structure of 
MNT, which enables easy tailoring, it could be possible, 
for example, to reduce liver uptake by substituting the cur-
rent (His)6-tag with an HEHEHE tag, which has recently 
been demonstrated to result in up to 19-fold lower liver 
accumulation.7
Materials and methods
Delayed type hypersensitivity reaction
Female C57 black/6J mice (n = 11, 20–25 g) were injected 
subcutaneously with DTox-HMP-NLS-αMSH (60 µL, 
2 mg/mL Dulbecco’s Modified Eagle Medium) mixed with 
Freund’s complete adjuvant (1:1, v/v, Sigma). After 5 days, 
one hind foot pad of each mouse was injected with DTox-
HMP-NLS-αMSH (40 µL, 2 mg/mL); the collateral foot 
was injected with only Dulbecco’s Modified Eagle Medium 
(experimental group). A control group of mice (n = 8) were 
not injected with MNT/Freund’s adjuvant. Edema was mea-
sured 24 hours later in foot pads of the experimental (mMNT,exp, 
and collateral, mDMEM,exp) and control (mDMEM,contr) groups8 and 
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Preparation of primary rabbit anti-MNT 
antibodies
The antibodies against MNT were raised in rabbits, accord-
ing to the method described by Burns.9 Briefly, 1-year old 
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Figure S2 Photocytotoxicity of DTox-HMP-NLS-EGF-bacteriochlorin p before (squares) and after (triangles) freeze-drying and reconstitution. The A431 cells were seeded 
into 96-well plates at a density of 2000 cells per well. After 24 hours, the cells were incubated for 20 hours at 37°C with DTox-HMP-NLS-EGF-bacteriochlorin p conjugate, 
washed three times with Hanks’ solution, placed into Dulbecco’s Modified Eagle Medium supplemented with 10% fetal calf serum for 3 hours, washed three times with 
Hanks’ solution, and placed into Dulbecco’s Modified Eagle Medium with 2 mg/mL bovine serum albumin. The cells were then illuminated with a slide projector at 270 kJ/m2 
and grown under 5% CO2. Survival of cells in wells not exposed to MNT-photosensitizer was considered as 100% survival. Cell viability was determined after 3–4 days 
using methylene blue staining according to the method of Finlay et al.2 EC50 values were calculated by nonlinear regression according to a four-parameter logistic equation 
(SigmaPlot 10). The experiments were carried out in six repeats, and error bars are the SEM.
Abbreviations: MNT, modular nanotransporter; DTox, translocation domain of diphtheria toxin; HMP, Escherichia coli hemoglobin-like protein; NLS, nuclear localization 
sequence; EGF, epidermal growth factor; SEM, standard error of the mean.
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Figure  S3  Biodistribution  of  125I  activity  in  female  B16-F1  melanoma-bearing  C57 
black/6J mice 3 hours after intravenous injection of 850 µg of 125I-labeled DTox-HMP-
NLS-αMSH. The concentration of radioactivity in different organs is expressed as %ID/g 
and presented as an average value from three animals ± SEM. Female C57 black/6J mice 
were inoculated subcutaneously with 1⋅106 B16-F1 murine melanoma cells and 13 days 
later, 850 µg (specific activity 6.5 µCi/mg) of 125I-labeled DTox-HMP-NLS-αMSH were 
injected intravenously in 500 µL of saline with 50 µg/mL gentamicin. Three hours after 
injection, the mice were anesthetized, euthanized, and their tumors and other organs 
and tissues were removed, weighed, and counted for 125I (RiaGamma 1271, LKB). The 
concentration of radioactivity was calculated as a ratio of 125I counts per gram of tissue.
Abbreviations:  MNT,  modular  nanotransporter;  DTox,  translocation  domain  of 
diphtheria toxin; HMP, Escherichia coli hemoglobin-like protein; NLS, nuclear locali-
zation sequence; EGF, epidermal growth factor; SEM, standard error of the mean.
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female rabbits (weight approximately 3.5 kg) were firstly 
immunized subcutaneously with 0.7 mL at each site using a 
HMP-NLS-αMSH and complete Freund’s adjuvant mixture 
(1:1, final concentration of HMP-NLS-αMSH 0.35 mg/mL). 
The injections were performed into two rows of four sites 
equidistantly spaced along the rabbit’s back and into both 
knee joint capsules. Rabbits were reimmunized three more 
times by subcutaneous injections of 0.5 mL each into four 
sites on the back at 7, 37, and 44 days. Donor bleeds were 
taken from an ear artery after the second and third immuni-
zations. The antiserum was separated from the clotted blood 
by centrifugation and stored at -20°C.
The immunoglobulin fraction was obtained by ammo-
nium persulfate precipitation. Briefly, cooled to 4°C, ammo-
nium persulfate solution (800 g/L) was added to antiserum 
at a final concentration of 28%. The resulting mixture was 
centrifuged at 4°C at 20,000 g for 20 minutes, and the 
supernatant was then precipitated again by ammonium 
persulfate (up to 50%) and centrifuged as described above. 
The pellet was dissolved in phosphate-buffered saline. This 
procedure was repeated twice. The purified immunoglobulin 
fraction was then finally purified by affinity chromatography 
using the immobilized antigen on CNBr Sepharose. The 
affinity of the purified antibodies to the antigen was assayed 
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Figure S4 Kinetics of tumor uptake of 125I activity after intravenous injection of 
11 µg 125I-labeled DTox-HMP-NLS-αMSH in B16-F1 melanoma-bearing C57 black/6J 
mice.  The  concentration  of  radioactivity  in  tumor  is  expressed  as  %ID/g  and 
presented as an average value from three animals ± SEM.
Abbreviations: iv, intravenous; MNT, modular nanotransporter; DTox, translocation 
domain of diphtheria toxin; HMP, Escherichia coli hemoglobin-like protein; NLS, nuclear 
localization sequence; EGF, epidermal growth factor; SEM, standard error of the mean.
by plate-trapped double-antibody sandwich enzyme-linked 
immunosorbent assay.10
Tumor response
Tumor growth was measured at regular intervals with micro-
calipers in two orthogonal dimensions; tumor volume was 
calculated according to formula V = 0.5 × length × width. 
Animals were euthanized when the tumor volume exceeded 
1200 mm3, in the case of tumor ulceration, or other signs of 
animal distress. Survival was recorded as the percentage of 
animals surviving on a given day.
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